Late-stage sepsis suppresses immune system

January 11, 2012 By Jim Dryden, Washington University School of Medicine in St. Louis
In a sepsis patient's lung cells (left), brown indicates a protein with the potential to "turn off" T-cells. Lung cells from a patient without sepsis remain blue (right), indicating the protein is not present. Credit: 2011 AMERICAN MEDICAL ASSOCIATION

(Medical Xpress) -- Patients who die from sepsis are likely to have had suppressed immune systems that left them unable to fight infections, researchers at Washington University School of Medicine in St. Louis have shown.

The findings suggest that therapies to rev up the may help save the lives of some patients with the disorder. Sepsis is a severe illness in which overwhelm the bloodstream.

The researchers compared taken from the lungs and spleens of 40 patients who had died of sepsis to those of patients who died from other causes. They reported their findings in the .

“More than 225,000 people die each year from sepsis, and developing more effective therapies has been challenging,” says senior investigator Richard S. Hotchkiss, MD, professor of anesthesiology. “This project was focused on trying to understand the mechanisms that underlie how the immune system responds to sepsis.”

That’s been an important question because the onset of sepsis usually includes what doctors call a “cytokine storm,” when the body’s immune system produces a massive inflammatory response. Some patients die during this initial phase. But others survive, including a significant number of patients whose sepsis evolves into a longer, chronic phase.

“These patients often get new infections,” says co-investigator Jonathan M. Green, MD, professor of medicine and of pathology and immunology. “They come into the ICU very sick, and we try to get them over that hump, but then they get stuck and don’t get better. They typically develop new infections, either a infection or pneumonia.”

Green, a pulmonary and critical care specialist, and Hotchkiss, an anesthesiologist, have worked together for years treating patients in the ICU at Barnes-Jewish Hospital. But the new research — launched over a cup of coffee — brought them together for the first time in the laboratory.

Hotchkiss had been collecting tissue samples from patients who died from sepsis, and Green brought expertise in lung function and immunology to the project. By analyzing the tissue samples, they determined that sepsis patients’ immune systems were, indeed, suppressed.

First author Jonathan S. Boomer, PhD, analyzed the tissue to determine whether key cells, called T-cells, were activated to respond to secondary infections like pneumonia or whether those cells were defective.

“We found that these T-cells were not able to function in the ways required to fight an infection,” says Boomer, a research instructor in medicine. “T-cells were present in both the lung and the spleen, but they failed to mount an effective immune response.”

Further study revealed that the T-cells sent to the lung to fight infection were stripped of their ability to mount an immune response, possibly by the lung cells themselves.

“It’s as if there’s a switch on the T-cell,” Green says. “But something’s got to flip that switch, and the finger is actually on lung cells. It may be that these T-cells are unable to function properly because cells in the aren’t allowing it.”

Hotchkiss’ laboratory found a similar mechanism at work in the spleen. He says taken together, the findings suggest a new direction for sepsis therapy.

“A real benefit of this study is that it points to how the paradigm for treating sepsis should change,” Hotchkiss says. “It’s pretty clear from this study that in some patients, we need to find ways to activate T-cells to fight sepsis.”

He says potential treatment strategies include blocking a cell-death pathway to rev up the T-cells. Another option may involve treatment with a substance called interleukin-7 (IL-7), which is known to activate T-cells.

A major caveat is that it’s not clear which patients would benefit from treatments that boost the immune response. The researchers plan to continue their collaboration as they work to answer that question.

Explore further: Researchers find chemical signals that initiate the body's immune response

More information: Boomer JS, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA, vol. 306 (23), pp. 2594-2605, Dec. 21, 2011.

Ward, PA, Immunosuppression in sepsis (editorial), JAMA

Related Stories

Researchers find chemical signals that initiate the body's immune response

September 9, 2011
(Medical Xpress) -- University of Florida researchers have identified two key steps required to activate the body’s innate immune system, its first line of defense against infection.

Findings suggest that severe sepsis can lead to impairment of immune system

December 20, 2011
An analysis of lung and spleen tissue from patients who died of sepsis revealed certain biochemical, cellular and histological findings that were consistent with immunosuppression, according to a study in the December 21 ...

'Blueprint' for blocking MMP may unlock new treatments for deadly blood infection

May 18, 2011
Researchers studying the life threatening infectious disease sepsis have discovered how the infection can lead to a fatal inflammatory response through blood vessel cells. The research, which is published in EMBO Molecular ...

Researchers find potential new way to fight sepsis

June 10, 2011
By digging a little deeper, researchers may have found a potential target for reversing the deadly blood infection sepsis.

Recommended for you

Quintupling inhaler medication may not prevent asthma attacks in children

March 19, 2018
Children with mild to moderate asthma do not benefit from a common practice of increasing their inhaled steroids at the first signs of an asthma exacerbation, according to clinical trial results published in The New England ...

How allergens trigger asthma attacks

March 19, 2018
A team of Inserm and CNRS researchers from the Institute of Pharmacology and Structural Biology have identified a protein that acts like a sensor detecting allergens in the respiratory tract that are responsible for asthma ...

Single steroid-bronchodilator treatment for control and rescue improves persistent asthma

March 19, 2018
When it comes to treating teens and adults with persistent asthma, using a single corticosteroid and long-acting bronchodilator treatment for both daily asthma control and for rescue relief during sudden asthma attacks is ...

Obesity and health problems: New research on a safeguard mechanism

March 16, 2018
Obesity and its negative impacts on health - including metabolic syndrome, type-2 diabetes mellitus and cardiovascular complications - are a global pandemic (Taubes, 2009). The worldwide incidence of obesity has more than ...

Immune system 'double agent' could be new ally in cancer fight

March 16, 2018
St. Jude Children's Research Hospital scientists have discovered that an enzyme called TAK1 functions like a "double agent" in the innate immune response, serving as an unexpected regulator of inflammation and cell death. ...

Artificial sweetener Splenda could intensify symptoms in those with Crohn's disease

March 15, 2018
In a study that has implications for humans with inflammatory diseases, researchers from Case Western Reserve University School of Medicine and colleagues have found that, given over a six-week period, the artificial sweetener ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.